Logo
Menu
  • Who We Are
  • How We Invest
  • Our Portfolio
    • Abzena
    • Ixlayer
    • Kiniciti
    • PathAI
  • Blog
  • Careers
  • Contact
Biomanufacturing: A Growing Field

Biomanufacturing: A Growing Field

by Biospring | Aug 1, 2022 | Advanced Therapy, Biologics, Biomanufacturing, CDMO, Cell and Gene Therapy, CGT, Drug Development, Life Sciences Technology

For a biotech company, discovering a new therapeutic candidate is a years-long, herculean achievement. A crucial question post-discovery is, can the drug be manufactured at scale? Companies must ensure that they can procure enough of a new therapy for clinical trials...
Driving Drug Development with Data Science

Driving Drug Development with Data Science

by Biospring | Apr 26, 2022 | Data Science, Digital Health, Drug Development, Drug Discovery, Janssen, Najat Khan

We were delighted to host a discussion with Najat Khan, PhD, Chief Data Science Officer and Global Head of Strategy and Operations, Janssen Research & Development (R&D), Johnson and Johnson. As the Chief Data Science Officer, Dr. Khan leads a team of 100+ data...
Proteomics 101

Proteomics 101

by Biospring | Apr 26, 2022 | DNA, Drug Development, Drug Discovery, Life Sciences Technology, Proteins, Proteome, Proteomics

Proteomics is the study of proteins (the proteome) in a cell, tissue, or organism. This emerging sector of the life sciences is helping scientists gain a deeper understanding of molecular biology. Proteins are large, complex molecules present in all living organisms....
Synbio 101: A primer on the next big life sciences technology

Synbio 101: A primer on the next big life sciences technology

by Biospring | Apr 25, 2022 | DNA, Drug Development, Drug Discovery, Manufacturing, Pharma, Supply Chain, Sybio, Synthetic Biology

Synthetic biology (synbio) is a life sciences technology that is transforming a broad range of industries including agriculture, chemicals, food, and medicine. Synbio applies engineering principles to biology and uses genomics to “code” organisms to yield a desired...
Abzena update with Sven Lee

Abzena update with Sven Lee

by Biospring | Apr 25, 2022 | Abzena, Biologics, Biotech, CDMO, COVID-19, Drug Development, Drug Discovery, Drug Manufacturing, Pharma, Sven Lee

We shared an overview on Abzena following our investment in July. Over the past few months, Abzena has launched a new facility in San Diego and has made several executive hires. We recently spoke with Sven Lee, Chief Business Officer at Abzena, and he provided us with...
Outsourced Manufacturing Key to Future of Drug Development

Outsourced Manufacturing Key to Future of Drug Development

by Biospring | Apr 24, 2022 | Abzena, Biologics, Biotech, CDMO, Drug Development, Pharma

Over the past few months, the COVID-19 pandemic has revealed gaps in the global pharmaceutical supply chain for drugs in clinical trials and for marketed drugs. Drug manufacturing can be a long and complex process requiring specialized expertise. The biopharmaceutical...

Recent Posts

  • Biospring Partners Welcomes Industry Executives To Its Advisory Board
  • Biomanufacturing: A Growing Field
  • Interview with Zach Weinberg
  • Driving Drug Development with Data Science
  • Proteomics 101

Recent Comments

No comments to show.

Newsletter

Thank you for subscribing!

Subscribe